Scholarlink

Purpose <p>Infections during neutropenia are​ a potentially life-threatening complication​ in pediatric oncology. International guidelines recommend antipseudomonal β-lactam monotherapy for stable patients, however, modification​ to carbapenems often occurs without confirmed infection.​</p> Methods <p>We conducted​ a retrospective cohort study​ at​ a single tertiary pediatric oncology center to assess the impact​ of​ a carbapenem-sparing AMS intervention​ in children during neutropenia. All pediatric cancer patients with​ at least one episode​ of​ suspected infection between January 2021 and October 2024 were included.​ The intervention combined training, updated standard operating procedures, multidrug-resistant (MDR) surveillance swabs, and​ a structured protocol reassessing meropenem treatment​.</p> Results <p>Among 254 patients, 116 met the inclusion criteria, accounting for 432​ episodes (270 pre- and 162 post-intervention). Re-modification​ of antimicrobial therapy from meropenem​ to piperacillin/tazobactam was achieved​ in​ 16​ of​ 50 post-intervention episodes. The median duration​ of meropenem treatment decreased from​ 9​ to​ 6&#xa0;days​ (<i>p​</i> = <i>0.006</i>). Interrupted time series analysis showed​ a non-significant reduction​ in meropenem use, corresponding​ to​ an estimated decline​ of 40.7&#xa0;days of therapy (DOT) per 1000 patient-days per quarter. Mortality was unchanged&#xa0;(3.8%​ vs 4.3%).</p> Conclusion <p>Our findings demonstrate that a structured AMS intervention is feasible and effective​ in pediatric oncology, reducing unnecessary meropenem exposure without compromising safety. While this approach may serve​ as​ a model for broader multicenter efforts​ to promote individualized, evidence-based antimicrobial use, the low number​ of blood stream infections (BSI)​ in our cohort limits the ability​ to draw definitive conclusions about the clinical impact​ of MDR screening​ on infection-related outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of an antimicrobial stewardship intervention on carbapenem use in children with cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月1日

查看全文
  • Sarina K. Butzer,
  • Katrin Mehler,
  • André Oberthuer,
  • Lena M. Biehl,
  • Benjamin Kuehne,
  • Pablo Landgraf,
  • Thorsten Simon,
  • Norma Jung

摘要

Purpose

Infections during neutropenia are​ a potentially life-threatening complication​ in pediatric oncology. International guidelines recommend antipseudomonal β-lactam monotherapy for stable patients, however, modification​ to carbapenems often occurs without confirmed infection.​

Methods

We conducted​ a retrospective cohort study​ at​ a single tertiary pediatric oncology center to assess the impact​ of​ a carbapenem-sparing AMS intervention​ in children during neutropenia. All pediatric cancer patients with​ at least one episode​ of​ suspected infection between January 2021 and October 2024 were included.​ The intervention combined training, updated standard operating procedures, multidrug-resistant (MDR) surveillance swabs, and​ a structured protocol reassessing meropenem treatment​.

Results

Among 254 patients, 116 met the inclusion criteria, accounting for 432​ episodes (270 pre- and 162 post-intervention). Re-modification​ of antimicrobial therapy from meropenem​ to piperacillin/tazobactam was achieved​ in​ 16​ of​ 50 post-intervention episodes. The median duration​ of meropenem treatment decreased from​ 9​ to​ 6 days​ (p​ = 0.006). Interrupted time series analysis showed​ a non-significant reduction​ in meropenem use, corresponding​ to​ an estimated decline​ of 40.7 days of therapy (DOT) per 1000 patient-days per quarter. Mortality was unchanged (3.8%​ vs 4.3%).

Conclusion

Our findings demonstrate that a structured AMS intervention is feasible and effective​ in pediatric oncology, reducing unnecessary meropenem exposure without compromising safety. While this approach may serve​ as​ a model for broader multicenter efforts​ to promote individualized, evidence-based antimicrobial use, the low number​ of blood stream infections (BSI)​ in our cohort limits the ability​ to draw definitive conclusions about the clinical impact​ of MDR screening​ on infection-related outcomes.